Literature DB >> 32643115

Pathological Predictors of Response to Neoadjuvant Treatment in Rectal Carcinoma.

Mona Malekzadeh Moghani1, Sam Alahyari2, Afshin Moradi3, Malihe Nasiri4.   

Abstract

PURPOSE: Neoadjuvant chemoradiotherapy has now become a standard treatment for rectal cancer. Recently, attempts have been made to predict the response rate to this treatment to decide whether or not it must be performed. However, tissue factors for predicting the response rate is not cohesively reviewed.
METHODS: Eighty-three patients with rectal cancer, all under neoadjuvant chemoradiotherapy and subsequent surgery, were examined for tissue factors in the biopsy sample. The tissue factors examined include tumor differentiation grade, lymphovascular invasion, perineural invasion, pathological stage, and lymphocytic infiltration. Lymphocytic infiltration was investigated by immunohistochemistry for CD8 T lymphocyte in biopsy samples.
RESULTS: In this study, tissue factors were found to play a decisive role in predicting response to neoadjuvant treatment. The most important factor was the pathological stage, which has the highest correlation with response to treatment. There is a significant relationship between CD8 lymphocyte infiltration and response to treatment (P value = 0.018). Primary perineural invasion and lymphovascular invasion also have a significant meaningful relationship with response to treatment (P value = 0.021 and P value = 0.036).
CONCLUSION: In this study, it was determined that the investigated factors have a significant relationship with response to treatment and could be used to predict the response to treatment, and if a low possibility of positive response exists, prevention of the complications of neoadjuvant chemoradiotherapy for the patients could occur.

Entities:  

Keywords:  Neoadjuvant therapy; Pathology; Predictive marker; Prognosis; Rectal cancer

Year:  2021        PMID: 32643115     DOI: 10.1007/s12029-020-00450-8

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  9 in total

1.  Epidemiology of Neuroendocrine Tumors in an Iranian Population.

Authors:  Mona MalekZadeh; Sam Alahyari; Saleh Sandoughdaran; Hanieh Zham
Journal:  Arch Iran Med       Date:  2017-10       Impact factor: 1.354

2.  Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?

Authors:  Julia Schollbach; Stefan Kircher; Armin Wiegering; Florian Seyfried; Ingo Klein; Andreas Rosenwald; Christoph-Thomas Germer; Stefan Löb
Journal:  Cancer Immunol Immunother       Date:  2019-01-22       Impact factor: 6.968

Review 3.  Epidemiology of colorectal cancer.

Authors:  Andrew R Marley; Hongmei Nan
Journal:  Int J Mol Epidemiol Genet       Date:  2016-09-30

4.  Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer.

Authors:  Feifei Teng; Dianbin Mu; Xiangjiao Meng; Li Kong; Hui Zhu; Sujing Liu; Jianbo Zhang; Jinming Yu
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

5.  High preoperative serum globulin in rectal cancer treated with neoadjunctive chemoradiation therapy is a risk factor for poor outcome.

Authors:  Qingguo Li; Xianke Meng; Lei Liang; Ye Xu; Guoxiang Cai; Sanjun Cai
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

6.  Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer.

Authors:  Koji Yasuda; Takako Nirei; Eiji Sunami; Hirokazu Nagawa; Joji Kitayama
Journal:  Radiat Oncol       Date:  2011-05-16       Impact factor: 3.481

7.  Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.

Authors:  Shinji Matsutani; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Shigetomi Nakao; Kosei Hirakawa; Masaichi Ohira
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

Review 8.  Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications.

Authors:  Monirath Hav; Louis Libbrecht; Liesbeth Ferdinande; Karen Geboes; Piet Pattyn; Claude A Cuvelier
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

Review 9.  Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer.

Authors:  Raquel Conde-Muíño; Marta Cuadros; Natalia Zambudio; Inmaculada Segura-Jiménez; Carlos Cano; Pablo Palma
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  9 in total
  5 in total

1.  Nomograms and risk score models for predicting survival in rectal cancer patients with neoadjuvant therapy.

Authors:  Fang-Ze Wei; Shi-Wen Mei; Jia-Nan Chen; Zhi-Jie Wang; Hai-Yu Shen; Juan Li; Fu-Qiang Zhao; Zheng Liu; Qian Liu
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

Review 2.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

Review 3.  Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Adile Orhan; Faisal Khesrawi; Michael Tvilling Madsen; Rasmus Peuliche Vogelsang; Niclas Dohrn; Anne-Marie Kanstrup Fiehn; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

4.  Impact of Positive Family History on the Survival of Breast Cancer.

Authors:  Mona Malekzadeh Moghani; Sam Alahyari; Malihe Nasiri
Journal:  Iran J Public Health       Date:  2022-07       Impact factor: 1.479

5.  The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer.

Authors:  Ali Yaghobi Joybari; Behnaz Behzadi; Payam Azadeh; Sam Alahyari
Journal:  Iran J Pathol       Date:  2021-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.